1 completed, 1 withdrawn. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Carbon C 11 Alpha-methyltryptophan: new trials by email Literature Review of Carbon C 11 Alpha-methyltryptophan trials Research Report on Carbon C 11 Alpha-methyltryptophan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm Carbon C 11 Alpha-methyltryptophan, Laboratory Biomarker Analysis, Positron Emission Tomography - Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 4 | 2018-06-20 | 2025-04-10 |
| C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer Adenovirus-p53 transduced dendritic cell vaccine, 1-methyl-D-tryptophan, Carbon C 11 alpha-methyltryptophan - Breast Cancer | Not applicable | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2013-01-01 | 2017-02-23 |
Breast Neoplasms (1) · Neoplasm Metastasis (1) · Serotonin Syndrome (1)
Barbara Ann Karmanos Cancer Institute (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
United States (1)
Anthony Shields (1) · Hatem Soliman, M.D. (1)
P30CA022453 (1)